Objectives: To evaluate the prevalence of antimicrobial resistance and selected antimicrobial resistance mechanisms in Shigella isolates recovered in outpatients from 1997 to 2009 in China.
Introduction
Shigella species are a common cause of community-acquired bacterial gastroenteritis in both developing and industrialized countries. 1 -3 Clinical manifestations of shigellosis may vary from asymptomatic infection to severe dysentery with bloody diarrhoea. In healthy adults, shigellosis will typically resolve within 4 -7 days, even without treatment. But life-threatening complications can occur in severe cases and appropriate antimicrobial treatment given early in the course will reduce the duration of symptoms and the transmission rate by shortening the period of pathogen excretion. 4 Major obstacles to the control of shigellosis include the ease of transmission from person to person and the rapid development of antimicrobial resistance. 5 Multidrug-resistant (MDR; resistant to three or more classes of antimicrobial) Shigella isolates have been reported worldwide and few reliable treatment options exist, particularly in developing countries where cost and practicality are paramount considerations. 6 The recent emergence of ciprofloxacin-or extended-spectrum-cephalosporin-resistant Shigella isolates further narrows the choice of effective antimicrobials. 7, 8 A few studies in China have analysed the antimicrobial resistance profiles of Shigella at a local level. 1, 9 As a fast-growing country, there is no long-term study for Shigella antimicrobial resistance in recent years. The objectives of the present study were to evaluate the prevalence of antimicrobial resistance and selected antimicrobial resistance mechanisms in Shigella isolates recovered from 1997 to 2009 in China.
Materials and methods

Bacterial isolates and serotyping
A total of 301 Shigella isolates recovered from stool samples of individual outpatients with diarrhoea were collected in hospitals of Beijing, Chengdu and Urumqi from 1997 to 2009. All Shigella isolates were identified by API 20E test (bioMérieux, Beijing, China) and serotyped by slide agglutination with commercial antisera (Tianrun Bio-Pharmaceutical Co., Ltd, China) according to the manufacturer's instructions. The confirmed Shigella isolates were kept in brain heart infusion broth with 50% glycerol at 2808C for further study.
Antimicrobial susceptibility testing
The MICs of 11 antimicrobials, i.e. ampicillin, cefepime, cefoxitin, ceftazidime, cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, nalidixic acid, tetracycline and trimethoprim/sulfamethoxazole, were determined using the broth microdilution method. All susceptibility results were interpreted according to CLSI interpretive standards. 10 Isolates with MICs of cefotaxime or ceftazidime higher than 1 mg/L were further screened for extended-spectrum b-lactamase (ESBL) production by determination of synergy between 0.25 -128 mg/L ceftazidime or cefotaxime and 4 mg/ L clavulanic acid. Isolates showing a ≥8-fold decrease in MIC of either ceftazidime or cefotaxime tested in combination with clavulanic acid versus its MIC tested alone were considered as producing ESBL. Escherichia coli ATCC 25922, E. coli ATCC 35218 and Klebsiella pneumoniae ATCC 700603 were used as quality control organisms in antimicrobial susceptibility experiments.
PFGE
Shigella isolates producing ESBL or resistant to ciprofloxacin were analysed by PFGE to determine DNA fingerprinting profiles resulting from digestion with restriction enzyme XbaI (New England Biolabs, Beijing) according to the procedures developed by the CDC PulseNet programme. 11 The interpretation of the PFGE patterns was performed with BioNumerics software (Applied Maths, St-Martens-Latern, Belgium) using the Dice similarity coefficient. The tree indicating relative genetic similarity was constructed on the basis of the unweighted pair group method of averages (UPGMA) and a position tolerance of 1%. Clusters were defined as DNA fingerprinting profiles sharing ≥90% similarity (C1, C2, C3, . . .) and PFGE patterns were defined as ≥95% similarity.
PCR amplification and DNA sequence analysis
The quinolone resistance-determination regions (QRDRs) of gyrA, gyrB, parC and parE in ciprofloxacin-resistant Shigella isolates were amplified by PCR. 12 Ciprofloxacin-resistant Shigella isolates were also screened by PCR targeting the transferable quinolone resistance determinants, including qnrA, qnrB, qnrS, aac-(6 ′ )-Ib and qepA. 13 -15 A multiplex PCR method was used to screen for bla CTX-M in ESBL-producing isolates and the sequences of bla CTX-M -like genes were analysed as previously described. 16, 17 Another multiplex PCR method was used to screen for plasmid-mediated AmpC-encoding genes in clavulanic-acid-resistant isolates. 18 All PCR products were either directly sequenced or cloned into the pMD18-T plasmid (Takara Biotechnology Cooperation, Dalian, China) for sequence analysis at Takara Biotechnology Cooperation. The sequences obtained were analysed by Sequencher 4.6 software (Gene Codes Corporation, Ann Arbor, MI, USA). The search for homologous sequences was performed by using the BLASTN program at the U.S. National Center for Biotechnology Information web site (http://www.ncbi.nlm.nih.gov/BLAST/). New bla CTX-M -like sequences identified in the present study have been submitted to the National Center for Biotechnology Information Data Libraries (GenBank) and the Lahey Clinic database (http://www.lahey.org/Studies/).
Conjugation experiments
The transmission capacity of b-lactamase-encoding genes from Shigella isolates was examined by a conjugation test using azide-resistant (MIC .300 mg/L) E. coli JM109 as the recipient. Briefly, donor and recipient overnight growth cultures were mixed in a ratio of 1 : 2 and inoculated on a 0.2 mm filter membrane (Millipore, USA) attached to MuellerHinton (MH) agar. After overnight incubation, the culture mixture on the membrane was suspended in 1 mL of MH broth and inoculated Other serotypes (n¼18) f1a (n¼14) f2a (n ¼127) f2b (n¼17) f4a (n¼42) fx (n ¼22) Zhang et al.
onto MH agar supplemented with azide (150 mg/L) and cefotaxime (8 mg/L). The acquisition of b-lactamase-encoding genes was confirmed by PCR as previously described. 16, 18 Statistical analysis
The differences in antimicrobial resistance frequencies were analysed by x 2 test and Matel-Haenszel test using Epi Info 6 software (www.cdc.gov/ epiinfo/). 
Results
Prevalence of serotypes
Antimicrobial resistance of Shigella isolates
Among 301 Shigella isolates, 4 isolates (1 S. dysenteriae type 1 isolate from Beijing in 2007 and 1 S. flexneri serotype f6 and 2 S. flexneri serotype f2a isolates from Urumqi in 2008) were susceptible to all 11 tested antimicrobials. Resistance to tetracycline was the most common (291/301, 96.7%), followed by nalidixic acid (283/301, 94.0%), ampicillin (258/301, 85.7%), trimethoprim/sulfamethoxazole (239/301, 79.4%) and chloramphenicol (231/301, 76.7%) ( Table 2 ).
The prevalence of ampicillin resistance of S. sonnei isolates in 2002 from Beijing (3/24, 12.5%) was significantly lower than that of other S. sonnei (30/37, 81.1%) and S. flexneri isolates (222/237, 93.7%) (P,0.01, x 2 ¼ 27.12). The prevalence of chloramphenicol resistance of S. sonnei isolates (7/61, 11.5%) was significantly lower than that (222/237, 93.7%) of S. flexneri isolates (P,0.01, x 2 ¼ 183.59). The prevalence of gentamicin resistance of S. sonnei isolates (29/61, 47.5%) was significantly higher than that (24/237, 10.1%) of S. flexneri isolates (P,0.01, x 2 ¼ 45.11). And the prevalence of gentamicin resistance of S. sonnei isolates in Beijing increased from 8.3% (2/24) Table 2) . Among the 301 isolates tested, 291 (96.7%) isolates showed MDR profiles. In total, 38 resistance profiles were identified and 34 were MDR profiles. The top six MDR profiles contained 241 isolates and a dominant MDR profile (ampicillin-chloram phenicol-nalidixic acid-tetracycline-trimethoprim/sulfamethoxazole) contained 119 S. flexneri isolates. Two resistance profiles (ampicillin-gentamicin-nalidixic acid-tetracycline-trimethoprim/ sulfamethoxazole and nalidixic acid-tetracycline-trimethoprim/ sulfamethoxazole) were dominated by S. sonnei isolates (Table 3) . 3 (13) 21 (96) 2 (8) 0 (0) 2 (8) 21 (96) 21 (88) 19 (86) 22 (92) 22 (100) 22 (92) 2007 7 (100) 12 (80) 7 (100) 2 (13) 0 (0) 13 (87) 7 (100) 15 (100) 6 (86) 15 (100) 7 (100) 15 (100) Chengdu 2008 9 (90) 12 (100) 9 (90) 2 (17) 1 (10) 12 (100) 10 (100) 12 (100) 10 (100) 12 (100) 9 (90) 12 ( 12 (100) 1 (100) 9 (75) 1 (100) 12 (100) 1 ( 10 (100) 1 (100) 9 (90) 1 (100) 10 ( 5 (63) 91 (90) 1 (13) 14 (14) 2 (25) 94 (93) 5 (63) 72 (71) 6 (75) 96 (95) 7 ( 33 (54) 222 (94) 7 (11) 24 (10) 29 (48) 226 (95) 55 (90) 180 (76) 57 (93) 231 (97) 58 (95) -, no isolates were recovered. were identified from Beijing (n¼ 2), Chengdu (n¼ 2) and Urumqi (n¼ 25). All ciprofloxacin-resistant isolates showed MDR profiles and two dominant resistance profiles were identified; ampicillin-chloramphenicol-ciprofloxacin-nalidixic acid-tetracycline-trimethoprim/sulfamethoxazole (n¼ 14) and ampicillinchloramphenicol-ciprofloxacin-nalidixic acid-tetracycline (n¼ 7) (Figure 1 ).
In total, 29 isolates exhibited an at least 8-fold decrease in the MIC of cefotaxime in combination with 4 mg/L clavulanic acid versus its MIC tested alone and three isolates showed resistance to both ceftazidime and clavulanic acid. All 32 isolates were recovered after 2002, i.e. S. flexneri serotype f4a (n¼ 12), f2a (n¼ 5), f1b (n¼ 2), fx (n¼5) and f2b (n¼ 1) and 7 S. sonnei isolates from Beijing (n¼ 3) and Urumqi (n¼ 4). Three isolates (two S. flexneri serotype fx isolates in 2004 and one S. flexneri serotype f4a isolate in 2006) from Urumqi showed resistance to cefoxitin, ceftazidime and clavulanic acid. Of these 32 isolates, 31 isolates showed MDR phenotypes and 6 isolates (1 S. flexneri serotype fx, 2 S. flexneri serotype f2a and 3 S. flexneri serotype f4a isolates) from Urumqi also showed resistance to ciprofloxacin (Figure 2 ).
Molecular analysis of the antimicrobial resistance determinants
In 30 ciprofloxacin-resistant S. flexneri isolates, no plasmidmediated quinolone resistance determinants and point mutations in QRDRs of GyrB and ParE were found, but three point mutations in QRDRs of GyrA and ParC were identified in each resistant isolate: GyrA (S83L, D87N) and ParC (S80I) in 18 isolates; and GyrA (S83L, D87G) and ParC (S80I) in 12 isolates.
Genes encoding CTX-M enzymes were detected in all 29 ESBLproducing isolates and genes encoding CMY-2 were detected in three clavulanic-acid-resistant isolates. Three isolates from Urumqi city carried bla CTX-M-15 -like genes with a unique point mutation in each isolate (K237R, V98A or Q60R) and four isolates from Urumqi city carried bla CTX-M-14 -like genes with a unique point mutation in each isolate (K114E, P148Q, S126G or Q86R). These seven new bla CTX-M genes have been assigned accession numbers in GenBank and the Lahey Clinic database as follows: JF274244, CTX-M-107; JF274245, CTX-M-108; JF274248, CTX-M109; JF274242, CTX-M-110; JF274243, CTX-M-111; JF274246, CTX-M-112; and JF274247, CTX-M-113. Other bla CTX-M genes were detected in 22 isolates: bla CTX-M-14 in 11 isolates; bla CTX-M-15 in 7 isolates; bla CTX-M-55 in 3 isolates; and bla CTX-M-3 in 1 isolate. All bla CTX-M and bla CMY-2 could be transferred to E. coli JM109 through conjugation.
PFGE analysis of Shigella isolates
Isolates containing bla CTX-M or bla CMY-2 or resistant to ciprofloxacin were analysed by PFGE. Two isolates containing bla CTX-M and one ciprofloxacin-resistant isolate could not be typed by PFGE. Of 29 ciprofloxacin-resistant S. flexneri isolates typed by PFGE, 13 PFGE patterns were identified and each serotype was grouped into a distinct PFGE pattern. Twenty-seven ciprofloxacin-resistant S. flexneri isolates were grouped into clusters 1 (13 isolates), 2 (11 isolates) and 3 (3 isolates). All isolates in cluster 2 were recovered from Urumqi city and isolates in cluster 1 were from Urumqi, Beijing and Chengdu (Figure 1) .
Of 31 isolates containing bla CTX-M or bla CMY-2 , 18 PFGE patterns were identified and 17 PFGE patterns consisted of Shigella isolates of one serotype. Twenty-two isolates were grouped into clusters 1 (two isolates), 2 (eight isolates), 3 (eight isolates) and 4 (four isolates). Except one isolate in cluster 2 that was from Beijing, all other isolates in clusters 1, 2 and 3 were recovered from Urumqi city. Isolates of S. flexneri and S. sonnei were grouped into distinct PFGE clusters or patterns. Six ESBLproducing and ciprofloxacin-resistant isolates were grouped into three PFGE clusters and five patterns (Figure 2 ).
Discussion
The genus Shigella includes Shigella boydii, S. dysenteriae, S. flexneri and S. sonnei. S. sonnei is the most common species in industrialized nations, whereas S. flexneri is the chief cause of endemic shigellosis in developing nations, 19, 20 but reasons for this distribution pattern have not been clearly clarified. Previous studies have reported that S. flexneri was the most frequently isolated Shigella species in mainland China. 1, 6 In the present study, S. flexneri was the dominant species in Urumqi during the study period, but S. sonnei became dominant among isolates in 2002 and 2007 from Beijing and 2008 from Chengdu city, which were two rapidly developing areas in China. A similar distribution pattern shift has also been recently observed in other fast developing countries. 21, 22 Since the main transmission route of Shigella was person to person contact or contaminated food consumption, 23 this significant shift might have resulted from the economic transition, the improvement in health resource availability and personal hygiene practices in these regions.
Our data showed that the Shigella genus had a strong capacity to rapidly accumulate antimicrobial resistance mechanisms. More than 90% of S. flexneri isolates in the present study showed MDR profiles and were highly resistant to older generation antimicrobials, such as ampicillin, chloramphenicol, nalidixic acid and tetracycline. A sharp resistance increase in S. sonnei in Beijing was observed; 12.5% of isolates in 2002 were resistant to ampicillin, but 80% of isolates in 2007 became ampicillin resistant-a similar trend was also observed for gentamicin. This rapid accumulation of resistance mechanisms in Shigella has also been described by other studies, which reported that the acquisition of resistance mechanisms was through mobile genetic elements. 6, 24 The precise causes of the observed capacity of resistance mechanism accumulation and high prevalence of MDR Shigella are not known. Different from Salmonella and E. coli, which are widely distributed, humans and a few primates are the only reservoirs of Shigella and its circulation among human beings is through person to person contact or consumption of contaminated food, which is facilitated by the low infective dose of Shigella (as few as 10 viable organisms). The prevalence of antimicrobial resistance in Shigella should be highly related to the volume and categories of antimicrobial consumption in the local community. Inappropriate prescription and the easy access of antimicrobials among outpatients could facilitate the selection and spread of MDR Shigella isolates in the local community. Studies estimated that half of outpatient antimicrobials were prescribed for inappropriate indications, such as viral illness. 25 In China, inappropriate prescriptions are more common, especially through intravenous infusion, since antimicrobial prescriptions are a profit source of hospitals and doctors. The over-the-counter sale of antimicrobials without prescription might be another reason for the resistance dissemination. Since most epidemic Shigella isolates in China are MDR as shown in our data, the abuse of antimicrobials in the community might be the main reason for the wide dissemination of MDR Shigella.
Fluoroquinolones and third-generation cephalosporins were two popular empirical options to treat severe gastrointestinal infections caused by pathogenic bacteria. 26 Ciprofloxacin has been recommended as the first-line antimicrobial for shigellosis treatment in the WHO guidelines for both adults and children. 27 But more than 90% of Shigella isolates in the present study showed resistance to nalidixic acid and decreased susceptibility (MIC ≥0.125 mg/L) to ciprofloxacin. These isolates had a high possibility of becoming ciprofloxacin resistant and causing treatment failure as shown in Salmonella infection. 28 The widespread nature of nalidixic acid resistance in the Shigella genus has also been documented as a unique characteristic in other studies of China and some Asian countries with easy access to antimicrobials. 6 But in countries with strict antimicrobial controls, such as the USA, only 1% of Shigella isolates were resistant to nalidixic acid and few ciprofloxacin-resistant isolates were identified nationwide. 3, 29 These data further emphasized the necessity of strict antimicrobial application control in developing nations. In the present study, 30 S. flexneri isolates (1 isolate in 1997 and 29 isolates after 2003) showed resistance to ciprofloxacin. The recognized ciprofloxacin resistance mechanisms in these isolates were chromosomal mediated and no plasmid-mediated quinolone resistance mechanisms were detected, which is different from E. coli, Salmonella and other studies of Shigella in China and other countries. 9, 30, 31 The ciprofloxacin MIC for these isolates was 4 -8 mg/L, which could be fully explained by the three point mutations in the QRDRs of GyrA and ParC as shown in a homologous recombination study of Salmonella Typhimurium. 32 The existence of other quinolone resistance mechanisms should raise the ciprofloxacin MIC to higher than 8 mg/L as reported in E. coli and Shigella. 29, 30 These ciprofloxacin-resistant S. flexneri isolates showed distinct genetic differences in both serotypes and PFGE profiles, which demonstrated that these isolates had multiple origins. No ciprofloxacin resistance was observed among S. sonnei isolates (n¼ 61) in the present study. This might be explained by the recent emergence of this subgroup in China and, since the prevalence of nalidixic-acid-resistant S. sonnei isolates was higher than 90%, it is predictable that ciprofloxacin-resistant S. sonnei isolates will show up and become more and more common if the abuse of antimicrobials in the local community is continued. The surveillance agencies should stay alert for the spread of ciprofloxacin-resistant S. flexneri isolates and the emergence of ciprofloxacin-resistant S. sonnei isolates.
In the present study, 32 Shigella isolates contained either bla CTX -M -or bla CMY-2 -harbouring plasmids, but the MIC of cefotaxime for these isolates ranged from 8 to .128 mg/L, which might be caused by the expression or copy number variation of ESBL-encoding genes. After being characterized by serotyping and PFGE, these isolates showed significant genetic variance and bla CTX-M sequence diversity (Figure 2 ). These data indicated that plasmids carrying different bla CTX-M were introduced into these isolates at various times. Especially, CTX-M-14, CTX-M-15 and CTX-M-55 have been identified as common ESBLs in Shigella and other species from both human and animal samples. 33 -35 Recently, a sudden dominance of bla CTX -M -harbouring plasmids in Shigella circulating in southern Vietnam has been reported. 8 Homologous comparison of bla CTX -M -or bla CMY-2 -containing plasmids should be conducted to explore the origins of these plasmids in Shigella. Similar to ciprofloxacin, few ESBL-producing Shigella isolates were detected in developed countries, which have good antimicrobial prescription systems. 3 Seven new bla CTX-M-14 or bla CTX-M-55 -like subtypes were identified in Shigella, which indicated that these genes might have been circulating among these Shigella isolates for a long time and have developed new subtypes through point mutations. In the present study, six ESBL-producing isolates were also resistant to Antimicrobial resistance of Shigella 2533 JAC ciprofloxacin, which would put patients under a high risk since empirical therapy with ceftriaxone or ciprofloxacin, a common practice, would be ineffective. To the best of our knowledge, this is the first report of ciprofloxacin-resistant ESBL-producing Shigella isolates in China.
Our data further confirmed that older antimicrobials, such as ampicillin, co-trimoxazole, tetracycline and nalidixic acid, no longer have a place in the treatment of shigellosis. The wide distribution of MDR Shigella isolates and the emergence of ESBLproducing and ciprofloxacin-resistant isolates clearly raise the perennial issue of strict control of antimicrobial prescription, improved sanitation and vaccine development, rather than new antibiotics, as a long-term solution to the plethora of shigellosis that disproportionately affects developing countries.
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